These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 12459003)
1. Summaries for patients. Bone loss after stopping estrogen or alendronate therapy. Ann Intern Med; 2002 Dec; 137(11):I31. PubMed ID: 12459003 [No Abstract] [Full Text] [Related]
2. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987 [TBL] [Abstract][Full Text] [Related]
3. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925 [TBL] [Abstract][Full Text] [Related]
4. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882 [TBL] [Abstract][Full Text] [Related]
5. Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis. Terauchi M; Obayashi S; Aso T Int J Gynaecol Obstet; 2006 Feb; 92(2):141-2. PubMed ID: 16305796 [No Abstract] [Full Text] [Related]
7. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT. Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Greenspan SL; Resnick NM; Parker RA JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324 [TBL] [Abstract][Full Text] [Related]
9. A negative feedback model for a mechanism based description of longitudinal observations. Application for bone turnover biomarkers. Boroujerdi MA; Schmidt S Methods Inf Med; 2013; 52(6):484-93. PubMed ID: 23907233 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of osteoporosis with estrogen]. Mizunuma H Nihon Rinsho; 2004 Feb; 62 Suppl 2():397-403. PubMed ID: 15035159 [No Abstract] [Full Text] [Related]
11. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773 [TBL] [Abstract][Full Text] [Related]
12. Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy. Palomba S; Orio F; Russo T; Colao A; Lombardi G; Zullo F Fertil Steril; 2004 Feb; 81(2):476-8. PubMed ID: 14967398 [TBL] [Abstract][Full Text] [Related]
13. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. Palomba S; Orio F; Colao A; di Carlo C; Sena T; Lombardi G; Zullo F; Mastrantonio P J Clin Endocrinol Metab; 2002 Apr; 87(4):1502-8. PubMed ID: 11932272 [TBL] [Abstract][Full Text] [Related]
14. Measurement of bone mineral density (BMD) with quantitative computed tomography (QCT) in postmenopausal osteoporosis: effect of estrogen. Zgliczyński S; Szulc P; Słowińska-Srzednicka J; Stopińska-Głuszak U; Misiorowski W; Jeske W; Snochowska H; Wagiel K; Walecki J Endokrynol Pol; 1992; 43(3):350-7. PubMed ID: 1345576 [TBL] [Abstract][Full Text] [Related]
15. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ; J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495 [TBL] [Abstract][Full Text] [Related]